Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model

Antimicrob Agents Chemother. 2009 Oct;53(10):4549-55. doi: 10.1128/AAC.00180-09. Epub 2009 Jul 20.

Abstract

In an in vitro pharmacodynamic model, linezolid attenuated the activity of aztreonam and ceftazidime against Escherichia coli. Conversely, synergy was detected at 24 and 48 h when daptomycin or vancomycin was added to aztreonam and ceftazidime. We conclude that significant yet underappreciated interactions may occur between gram-positive-spectrum and gram-negative-spectrum antibacterials.

MeSH terms

  • Acetamides / pharmacokinetics
  • Acetamides / pharmacology*
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology*
  • Aztreonam / pharmacokinetics
  • Aztreonam / pharmacology*
  • Ceftazidime / pharmacokinetics
  • Ceftazidime / pharmacology*
  • Daptomycin / pharmacokinetics
  • Daptomycin / pharmacology*
  • Drug Synergism
  • Drug Therapy, Combination
  • Escherichia coli / drug effects*
  • Linezolid
  • Microbial Sensitivity Tests
  • Oxazolidinones / pharmacokinetics
  • Oxazolidinones / pharmacology*
  • Vancomycin / pharmacokinetics
  • Vancomycin / pharmacology*

Substances

  • Acetamides
  • Anti-Bacterial Agents
  • Oxazolidinones
  • Vancomycin
  • Ceftazidime
  • Aztreonam
  • Linezolid
  • Daptomycin